Does Highmark Cover Dupixent? Prior Authorization, Costs, and Step Therapy Rules
Dupixent (dupilumab) is a monoclonal antibody biologic, made by Regeneron and marketed by Sanofi, that blocks the shared receptor component for interleukin-4 and interleukin-13. It is FDA-approved for several type 2 inflammatory conditions, including moderate-to-severe atopic dermatitis, uncontrolled asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, prurigo nodularis, and COPD with an eosinophilic phenotype. It is not the same molecule as omalizumab (Xolair), mepolizumab (Nucala), or tralokinumab (Adbry), which target different pathways in overlapping conditions.
Highmark Blue Cross Blue Shield plans typically place Dupixent on their specialty drug tier and cover it for FDA-approved indications, but every plan requires prior authorization, and most require documented failure or intolerance of at least one lower-step therapy before approving it. The exact clinical criteria, cost-sharing percentage, specialty pharmacy network, and appeal timelines differ by specific Highmark product (commercial, Medicare Advantage, employer-sponsored) and can change between plan years, so a member's own plan documents or a call to member services is the only reliable source for their individual terms.
At a glance
- FDA-approved indications / atopic dermatitis (age 6 months+), asthma (age 6+), CRSwNP (adults), eosinophilic esophagitis (age 1+, 40 kg+), prurigo nodularis (adults), COPD with type 2 inflammation (adults), verify current label at FDA.gov
- Coverage pattern / Dupixent is commonly covered on specialty tiers across major insurers, Highmark included, but plan-level tier placement and criteria are not standardized nationally
- Prior authorization / Required by essentially all payers, including Highmark, before the first fill
- Step therapy / Typically requires documented trial and failure of at least one conventional first-line therapy; the exact drugs and duration required are plan-specific
- Specialty pharmacy / Dupixent is dispensed through contracted specialty pharmacies rather than retail pharmacies under most insurance benefit designs
- Cost without insurance / Dupixent carries a list price in the tens of thousands of dollars per year; exact current pricing should be checked at the time of fill
- Copay assistance / Sanofi operates the Dupixent MyWay program for eligible commercially insured patients; eligibility rules and maximum benefit amounts are set by the manufacturer and can change
What is established, and what needs to be verified with Highmark directly
This article can confirm the following from stable, non-volatile sources: Dupixent's FDA-approved indications and general mechanism, the general existence of prior authorization and step therapy as standard utilization management tools used across the health insurance industry, and the general federal and state legal protections around urgent review timelines and appeal rights that apply broadly to insured patients, not specifically because a source described Highmark's policy.
This article cannot confirm, from the material available, the specific numeric thresholds Highmark uses in its current medical policy (for example, exact IGA score cutoffs, exact eosinophil counts, exact number of business days for a standard PA decision, or exact coinsurance percentages). Insurer medical policies are proprietary documents that change on a schedule set by the insurer, often annually, and no independently verifiable source was available to confirm Highmark's current specific numbers at the time of this draft. Where the original draft stated precise figures for Highmark's internal criteria, those figures could not be verified against a primary source and have been removed or reframed as "commonly required" industry patterns rather than confirmed Highmark rules.
Is Dupixent on Highmark's formulary?
Highmark, like most major commercial insurers, generally includes Dupixent on its specialty drug tier for FDA-approved uses. Specialty tier placement means higher cost-sharing than a generic or preferred brand drug, and it means the prescription is subject to medical necessity review before the plan will pay for it. This is standard industry practice for high-cost biologics and is not unique to Highmark or to Dupixent.
Because Highmark issues many distinct products (commercial PPO, HMO, EPO plans, employer self-funded plans with custom formularies, and Medicare Advantage plans), formulary tier and prior authorization criteria can differ from one Highmark member's plan to another's. A member should confirm current tier status and PA criteria through the Highmark member portal or by calling the number on their insurance card, rather than assuming the terms described in general coverage articles apply to their specific plan and plan year.
Prior authorization: what the process generally involves
Prior authorization is required by nearly every insurer, including Highmark, before Dupixent is dispensed for the first time. The prescribing physician's office submits clinical documentation, and the plan's pharmacy or medical review team evaluates it against the plan's published medical policy.
Federal and state rules generally require insurers to expedite review when a delay could seriously jeopardize a patient's health, and to provide standard determinations within a defined window, though the specific number of days varies by state and by whether the plan is fully insured or self-funded (self-funded employer plans are regulated primarily under federal ERISA rules rather than state insurance law). A member whose request is urgent should ask the prescriber's office to mark the request accordingly and should ask Highmark directly what timeline applies to their specific plan.
If Highmark denies the prior authorization, the prescriber can generally request a peer-to-peer conversation with a plan medical director, and the member can file a formal internal appeal. Pennsylvania-licensed plans are subject to Pennsylvania insurance law, which provides for external review by an independent review organization for denied specialty drug claims in many circumstances; a member should confirm whether this applies to their specific plan type, since fully insured Pennsylvania-regulated plans and self-funded ERISA plans are not always subject to identical appeal rules.
Step therapy: what "trying something first" usually means
Step therapy for Dupixent generally requires documentation that the patient tried and failed, or could not tolerate, at least one conventional first-line treatment before the biologic is approved. Across the industry, the typical pattern for atopic dermatitis involves documented use of prescription topical therapy, such as a topical corticosteroid or a topical calcineurin inhibitor, for a period of weeks to months. For asthma, the typical pattern involves documentation of inadequate control despite inhaled corticosteroids combined with a second controller medication. For CRSwNP, the typical pattern involves documented use of intranasal corticosteroids and, often, a prior sinus surgery or a documented reason surgery was not appropriate.
Whether Highmark's specific policy requires a systemic immunosuppressant trial (such as methotrexate or cyclosporine) in addition to topicals for adult atopic dermatitis, or accepts topical failure alone, is a plan-specific detail that could not be confirmed from available sources and should be checked against Highmark's current published medical policy for the member's specific product.
Verification checklist: what you can trust as stable versus what changes by plan and date
Use this checklist to distinguish general information about skin and hair treatments from details particular to your Highmark plan, your state, and the current date. Before making coverage decisions based on information in the second column, verify it directly with Highmark, your dermatologist's office, or your specialty pharmacy.
| Question | Stable fact (safe to rely on generally) | Plan- or date-specific (verify directly, and note the date you checked) |
|---|---|---|
| Is Dupixent FDA-approved for my condition? | The FDA label lists approved indications and age ranges; check the current label at accessdata.fda.gov for the exact wording | Whether your prescriber's intended use matches on-label use or is off-label for your specific diagnosis |
| Does insurance typically require prior authorization? | Yes, this is standard industry practice for specialty biologics | Highmark's specific PA form, submission portal, and current turnaround-time target for your plan |
| Does step therapy apply? | Step therapy is a common utilization management tool across insurers for this drug class | The exact drugs, doses, and duration Highmark currently requires you to have tried, which can differ by indication and plan year |
| Can I appeal a denial? | Internal appeal rights and, in many states, external independent review exist for denied specialty drugs | The specific appeal deadline, the process (peer-to-peer, written appeal, external review), and whether your plan is state-regulated or a self-funded ERISA plan with different rules |
| What will I pay? | Dupixent is a high-cost specialty biologic; expect meaningful cost-sharing without assistance | Your plan's actual coinsurance or copay tier, your deductible status this benefit year, and current Dupixent MyWay eligibility rules and maximum annual benefit, all of which the manufacturer and insurer can change |
| Which pharmacy fills it? | Specialty biologics are usually dispensed through a contracted specialty pharmacy, not a retail pharmacy counter | Which specific specialty pharmacy is in-network for your particular Highmark product this year |
| How often do I need to reauthorize? | Ongoing biologic therapy typically requires periodic reauthorization based on documented response | Highmark's current reauthorization interval and the specific clinical response criteria it requires for your indication |
What Dupixent typically costs, and where assistance can help
Dupixent carries a list price in the tens of thousands of dollars annually for standard adult dosing; exact current list pricing should be checked against the manufacturer's current pricing disclosure or the FDA label pricing information at the time of a fill, since list prices change. What a Highmark member actually pays out of pocket depends on their specific plan's deductible, coinsurance or copay structure for the specialty tier, and where they are in the plan year, none of which can be stated as a fixed number across "Highmark" as a whole.
Sanofi operates a copay assistance program, Dupixent MyWay, for eligible commercially insured patients, which can substantially reduce monthly out-of-pocket costs. Patients on Medicare, Medicaid, or other government insurance are generally not eligible for manufacturer copay cards under federal anti-kickback rules that apply broadly to drug copay assistance, but may qualify for separate patient assistance programs. Program terms, income eligibility, and maximum annual benefit amounts are set by the manufacturer and are subject to change, so current terms should be confirmed directly with the Dupixent MyWay program rather than assumed from this article.
Medicare Part D includes an annual out-of-pocket spending cap that took effect in 2025 under the Inflation Reduction Act; members with Highmark Medicare Advantage prescription drug coverage should confirm the current cap amount and how it applies to their specific plan, since cap amounts are indexed and can be adjusted in future years.
Coverage across Dupixent's approved indications
Dupixent's FDA-approved indications now include atopic dermatitis, asthma, CRSwNP, eosinophilic esophagitis, prurigo nodularis, and COPD with evidence of type 2 inflammation. Coverage policies for insurers generally extend to on-label use once prior authorization criteria are met, but the specific documentation required (biopsy results for eosinophilic esophagitis, oral corticosteroid dependence for asthma, eosinophil counts for COPD) is set by each plan's medical policy. The COPD indication is the most recently approved of the group, and coverage criteria for it may still be in the process of being finalized across some insurer plan documents; members considering Dupixent for COPD should confirm current coverage status with Highmark directly rather than assume parity with the longer-established indications.
Clinical trial evidence supports dupilumab's efficacy across these indications, including phase 3 trials in atopic dermatitis and asthma and dedicated trials for the newer indications. Readers who want indication-specific trial results should look them up directly in the primary literature or the FDA label rather than rely on secondhand percentage figures, since the specific numeric outcomes reported in earlier versions of this article could not be verified against a confirmed source in this review and have been removed rather than repeated with an unverified citation.
How to move a Dupixent approval forward
- Build the clinical record. The prescriber documents diagnosis severity, prior treatments tried with dates and outcomes, and any adverse reactions to first-line options. Objective measures relevant to the specific indication (severity scores, lab values, endoscopy results, imaging) strengthen the request.
- Submit the prior authorization request through whatever electronic portal or fax process Highmark currently designates for the member's specific plan.
- Track the timeline. Ask the prescriber's office to flag the request as urgent if a delay would seriously affect the patient's health, and ask Highmark directly what standard and expedited timelines apply.
- Prepare for a possible denial. If denied, ask about a peer-to-peer review, then a formal internal appeal, and ask specifically whether external independent review is available for the plan type.
- Coordinate the specialty pharmacy fill once approved, including copay assistance enrollment if eligible.
When to seek care regardless of coverage status
Insurance coverage questions should never delay evaluation of symptoms that need medical attention. Worsening skin infection, difficulty breathing, a significant asthma flare, or new or worsening swallowing difficulty (relevant to eosinophilic esophagitis) warrants prompt medical evaluation independent of where things stand with a prior authorization request. A pharmacy or insurance delay is not a reason to stop other prescribed treatments without talking to the prescribing clinician first.
